Amylyx is developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that targets the neuroinflammation and nerve cell death that characterize these disorders. The company’s therapeutic, AMX0035, is a proprietary combination of existing compounds that Amylyx has demonstrated have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models. AMX0035 is expected to enter clinical trials in ALS patients in 2017.
Amylyx’s approach is distinct from other therapeutic strategies in its focus on simultaneously ameliorating two key drivers of ALS clinical pathology, neuroinflammation and nerve cell death. Neuroinflammation and nerve cell death are also hallmarks of other neurodegenerative disorders, such as Alzheimer’s disease, suggesting Amylyx’s approach has potential in these conditions as well.